The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Open accessAbstract
BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No sufficient safety and efficacy data are available for DAPT with reduced-dose ticagrelor beyond 3 years”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
In the citing paper
“Reduced-dose ticagrelor (60 mg) decreased MACE compared with placebo (7.77% vs. 9.04%, respectively; HR 0.84; 95% CI, 0.74-0.95;P = 0.004; NNT 79), with no heterogeneity with respect to the diabetes sub-group”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
In the citing paper
“whereas it significantly increased TIMI major bleeding (2.3% vs. 1.06%, respectively; HR 2.32; 95% CI, 1.68-3.21;NNH 81)”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
In the citing paper
“dyspnoea, serious adverse events, and drug discontinuation rates.317”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [317]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E., Green, L. A., Hand, M. M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,348
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationAuthors Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,890
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,802
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Self-citation
Cited by
Sorted by citations
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citation2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationAboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P. H., Mauri, L., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 3,041
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
Self-citationRivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
“Current ACS guidelines recommend DAPT for up to 1 year after the acute event in patients without indication for OAC, while high-risk patients might require an even longer DAPT duration.(318,319) They do, however, also allow for shorter DAPT durations (3–6 months) in high bleeding risk ACS patients.”
Background2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationLevine, G. N., Bates, E., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,658
“Recommendations for Duration of DAPT in Patients With SIHD .”
BackgroundMethodInfluentialSelf-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Reed, G. W., Rossi, J., & Cannon, C. P. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30677-8 · Cited by 1,614
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,435
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction
The SCOT-HEART Investigators (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805971 · Cited by 1,390
“Beta-blocker 1357/4142 (33) 672/2070 (32) 685/2072 (33)”
2018 ESC/EACTS Guidelines on myocardial revascularization
Neumann, F., Sousa‐Uva, M., Ahlsson, A., Alfonso, F., BANNING, A. P., Benedetto, U., Byrne, R. A., Collet, J., Falk, V., Head, S. J., et al. (2019) · EuroIntervention · doi:10.4244/eijy19m01_01 · Cited by 1,278
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000404 · Cited by 1,355
Self-citationSteffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbüchel, H., Verhamme, P. B., Alings, M., Antz, M., Diener, H., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. F. (2015) · EP Europace · doi:10.1093/europace/euv309 · Cited by 1,129
Rivaroxaban in Peripheral Artery Disease after Revascularization
Bonaca, M. P., Bauersachs, R. M., Anand, S. S., Debus, E. S., Nehler, M. R., Patel, M. R., Fanelli, F., Capell, W. H., Diao, L., Jaeger, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2000052 · Cited by 1,045
Self-citationTicagrelor with or without Aspirin in High-Risk Patients after PCI
Mehran, R., Baber, U., Sharma, S. K., Cohen, D. J., Angiolillo, D. J., Briguori, C., Cha, J. Y., Collier, T. J., Dangas, G., Dudek, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908419 · Cited by 1,044
Self-citation2018 ESC/EACTS Guidelines on myocardial revascularization
Sousa-Uva, M., Neumann, F., Ahlsson, A., Alfonso, F., BANNING, A. P., Benedetto, U., Byrne, R. A., Collet, J., Falk, V., Head, S. J., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy289 · Cited by 1,025
Complete Revascularization with Multivessel PCI for Myocardial Infarction
Mehta, S. R., Wood, D. A., Storey, R. F., Mehran, R., Bainey, K. R., Nguyen, H., Meeks, B., Pasquale, G. D., López-Sendón, J., Faxon, D. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907775 · Cited by 982
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Valsecchi, M. E. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 874
Watanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.8145 · Cited by 874
Diagnosis and Treatment of Acute Coronary Syndromes
Bhatt, D. L., Lópes, R. D., & Harrington, R. A. (2022) · JAMA · doi:10.1001/jama.2022.0358 · Cited by 869
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C. W., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 823
Self-citationConnolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Self-citationHalliday, A. W., & Bax, J. J. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.03.004 · Cited by 660
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Hiatt, W. R., Fowkes, F. G. R., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Jones, W. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611688 · Cited by 636
Self-citationStroke genetics informs drug discovery and risk prediction across ancestries
Mishra, A., Malik, R., Hachiya, T., Jürgenson, T., Namba, S., Posner, D. C., Kamanu, F., Koido, M., Grand, Q. L., Shi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05165-3 · Cited by 623
“…54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin) 112 and FOURIER (further cardiovascular outcomes research with PCSK9 inhibition in patients with elevated risk) 113 trials were included in this…”
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Self-citation2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.009 · Cited by 668
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 586
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
Johnston, S. C., Amarenco, P., Albers, G. W., Denison, H., Easton, J. D., Evans, S. R., Held, P., Jonasson, J., Minematsu, K., Molina, C. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603060 · Cited by 530
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 502
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease
Anand, S. S., Caron, F., Eikelboom, J. W., Bosch, J., Dyal, L., Aboyans, V., Abola, M. T., Branch, K. R. H., Keltai, K., Bhatt, D. L., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.008 · Cited by 466
Self-citationIbáñez, B., James, S. K., Agewall, S., Antunes, M. J., Bucciarelli‐Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 479
Généreux, P., Giustino, G., Witzenbichler, B., Weisz, G., Stuckey, T., Rinaldi, M. J., Neumann, F., Metzger, D. C., Henry, T. D., Cox, D. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1323 · Cited by 458
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 467
Self-citationValgimigli, M., Bueno, H., Byrne, R. A., Collet, J., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P. H., Mauri, L., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx334 · Cited by 421
Self-citationInternational Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S. K., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D. K., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031164 · Cited by 409
Self-citationTherapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 413
Bonaca, M. P., Bhatt, D. L., Storey, R. F., Steg, P. G., Cohen, M. C., Kuder, J., Goodrich, E. L., Nicolau, J. C., Parkhomenko, A. N., Lopez-Sendon, J. L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.524 · Cited by 385
Self-citationKoushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
“Long-term treatment with ticagrelor, an antiplatelet medication, reduces cardiovascular events in patients with acute coronary syndrome [177, 178].”
BackgroundHahn, J., Song, Y. B., Oh, J. H., Cho, D., Lee, J. B., Doh, J., Kim, S., Jeong, J., Bae, J., Kim, B. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30493-8 · Cited by 380
Udell, J. A., Bonaca, M. P., Collet, J., Lincoff, A. M., Kereiakes, D. J., Costa, F., Lee, C. W., Mauri, L., Valgimigli, M., Park, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv443 · Cited by 371
“After exclusions, the remaining six trials met criteria for eligibility in the primary meta-analysis.(17,18,23) – 29 These trials, which comprised 33 435 participants randomized to a strategy of extended DAPT (n 1⁄4 20 203) vs.”
MethodSelf-citationTicagrelor in patients with stable coronary disease and diabetes
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908077 · Cited by 365
Self-citationACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M., & Angiolillo, D. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.057 · Cited by 375
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Self-citationJohansson, S., Rosengren, A., Young, K., & Jennings, E. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0482-9 · Cited by 344
“Results from a recent clinical trial suggest that prolonged dual antiplatelet therapy (DAPT) beyond the first year after an AMI is beneficial in terms of preventing vascular events [24].”
BackgroundValgimigli, M., Costa, F., Lokhnygina, Y. V., Clare, R. M., Wallentin, L. C., Moliterno, D. J., Armstrong, P. W., White, H. D., Held, C., Aylward, P. E., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw525 · Cited by 337
“In light of recent clinical trial data with DAPT regimens beyond 1 year showing further reduction of ischaemic events at the price of a similar increase in bleeding, the number of patients who may qualify for longer-term DAPT is going to increase.(14,15) Therefore, it is critical to understand the prognostic implicati…”
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 342
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rosselló, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 373
Self-citationChew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.06.789 · Cited by 326
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
“RECOMMENDATIONS FOR DURATION OF DAPT IN PATIENTS WITH SIHD . . . . . . . . . . . . . . . .”
BackgroundMethodInfluentialSelf-citationArnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Self-citationAntiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. J., Galli, M., Collet, J., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 318
Aboyans, V., Ricco, J., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T. U., Collet, J., Czerny, M., Carlo, M. D., Debus, S., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.07.018 · Cited by 1,027
Yeh, R. W., Kereiakes, D. J., Steg, P. G., Windecker, S., Rinaldi, M. J., Gershlick, A., Cutlip, D. E., Cohen, D. J., Tanguay, J., Jacobs, A. K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.003 · Cited by 277
Self-citationThe Primary Outcome Fails — What Next?
Pocock, S., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510064 · Cited by 275
Macle, L., Cairns, J. A., Leblanc, K., Tsang, T. S. M., Skanes, A. C., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 275
Lip, G. Y. H., Collet, J. P., Haude, M., Byrne, R., Chung, E. H., Fauchier, L., Halvorsen, S., Lau, D. H., López-Cabanillas, N., Lettino, M., et al. (2018) · EP Europace · doi:10.1093/europace/euy174 · Cited by 281
Self-citationESVM Guideline on peripheral arterial disease
Frank, U., Nikol, S., Belch, J. J. F., Boc, V., Brodmann, M., Carpentier, P., Chraim, A., Canning, C., Dimakakos, E. P., Gottsäter, A., et al. (2019) · VASA · doi:10.1024/0301-1526/a000834 · Cited by 275
2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4103 · Cited by 271
2020 Clinical practice guidelines for Stable coronary artery disease
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4076 · Cited by 313
Zhao, Q., Zhu, Y., Xu, Z., Cheng, Z., Mei, J., Chen, X., & Wang, X. (2018) · JAMA · doi:10.1001/jama.2018.3197 · Cited by 241
Bittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Circulation · doi:10.1161/cir.0000000000000405 · Cited by 229
Bhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216
Self-citationAntiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J., Fitzgerald, D. J., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 233
Self-citationComorbidities in clinical practice. Algorithms for diagnostics and treatment
Гегамович, О. Р., Simanenkov, V. I., Бакулин, И. Г., Бакулина, Н. В., Барбараш, О. Л., Boytsov, S. A., Афанасьевна, Б. С., Garganeeva, N. P., Doshchitsin, V. L., Karateev, A. E., et al. (2019) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2019-1-5-66 · Cited by 253
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 220
Self-citationEvidence-Based Medical Management of Peripheral Artery Disease
Bevan, G. H., & Solaru, K. W. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312142 · Cited by 241
Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31887-2 · Cited by 209
Self-citationMehta, S. R., Bainey, K. R., Cantor, W. J., Lordkipanidzé, M., Marquis‐Gravel, G., Robinson, S. D., Sibbald, M., So, D. Y. F., Wong, G. C., Abunassar, J. G., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.012 · Cited by 213
Park, D., Kwon, O., Jang, J., Yun, S., Park, H., Kang, D., Ahn, J., Lee, P. H., Lee, S., Park, S., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041766 · Cited by 210
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
Zaman, S. J., Wasfy, J. H., Kapil, V., Ziaeian, B., Parsonage, W. A., Sriswasdi, S., Chico, T., Capodanno, D., Colleran, R., Sutton, N. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00055-8 · Cited by 236
Baeßler, B., Mannil, M., Oebel, S., Maintz, D. C., Alkadhi, H., & Manka, R. (2017) · Radiology · doi:10.1148/radiol.2017170213 · Cited by 202
“Patients with myocardial scar after MI are at increased risk for arrhythmia and death (2), highlighting the relevance of detecting and characterizing myocardial scar to guide intensive secondary prevention (3).”
BackgroundPalmerini, T., Riva, D. D., Benedetto, U., Reggiani, M. L. B., Feres, F., Abizaid, A., Gilard, M., Morice, M., Valgimigli, M., Hong, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw627 · Cited by 201
Self-citationSabaté, M., Brugaletta, S., Cequier, A. R., Íñiguez, A., Serra, A., Jiménez‐Quevedo, P., Mainar, V., Campo, G. C., Tespili, M., den Heijer, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00548-6 · Cited by 197
Amarenco, P., Albers, G. W., Denison, H., Easton, J. D., Evans, S. R., Held, P., Hill, M. D., Jonasson, J., Kasner, S. E., Ladenvall, P., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30038-8 · Cited by 196
Self-citationBittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.512 · Cited by 200
Myocardial Infarction—From Atherosclerosis to Thrombosis
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 208
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 204
Luca, G. D., Damen, S. A. J., Camaro, C., Benit, E., Verdoia, M., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A. W., Zambahari, R., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00539 · Cited by 184
Baber, U., Dangas, G., Angiolillo, D. J., Cohen, D. J., Sharma, S. K., Nicolas, J., Briguori, C., Yu, J. M., Collier, T. J., Dudek, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa670 · Cited by 191
Self-citationUpdates on Acute Coronary Syndrome
Eisen, A., Giugliano, R. P., & Braunwald, E. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2049 · Cited by 182
Kedhi, E., Fabris, E., van der Ent, M., Buszman, P. E., von Birgelen, C., Roolvink, V., Żurakowski, A., Schotborgh, C. E., Hoorntje, J. C. A., Eek, C. H., et al. (2018) · BMJ · doi:10.1136/bmj.k3793 · Cited by 184
Capodanno, D., Mehran, R., Krucoff, M. W., Baber, U., Bhatt, D. L., Capranzano, P., Collet, J., Cuisset, T., Luca, G. D., Luca, L. D., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064473 · Cited by 180
Self-citationSwitching P2Y12-receptor inhibitors in patients with coronary artery disease
Rollini, F., Franchi, F., & Angiolillo, D. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.113 · Cited by 180
Helft, G., Steg, P. G., Feuvre, C. L., Georges, J., Carrié, D., Dreyfus, X., Furber, A., Leclercq, F., Eltchaninoff, H., Falquier, J.-F., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv481 · Cited by 177
Self-citationChiarito, M., Sanz‐Sánchez, J., Cannata, F., Cao, D., Sturla, M., Panico, C., Godino, C., Regazzoli, D., Reimers, B., Caterina, R. D., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30315-9 · Cited by 179
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca‐Fontán, F., Vecchio, L. D., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 189
Long-Term Evolution of Premature Coronary Artery Disease
Collet, J., Zeitouni, M., Procopi, N., Hulot, J., Silvain, J., Kernéis, M., Thomas, D., Lattuca, B., Barthélémy, O., Badie, Y. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1002 · Cited by 186
Bosch, J., Eikelboom, J. W., Connolly, S. J., Bruns, N. C., Lanius, V., Yuan, F., Misselwitz, F., Chen, E., Díaz, R., Alings, M., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.06.001 · Cited by 172
“Long-term treatment with the combination of aspirin and dipyridamole or aspirin and ticagrelor compared with aspirin alone, or the combination of vorapaxar with standard antiplatelet therapy also yielded benefits but none of these approaches reduced mortality.(16-18) The combination of aspirin and warfarin compared wi…”
BackgroundSelf-citationLong-Term Use of Cardiovascular Drugs
Rosselló, X., Pocock, S., & Julian, D. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.018 · Cited by 171
Metadata
- Authors
- Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., Bengtsson, O., Ophuis, T. O., Budaj, A., Theroux, P., Ruda, M., Hamm, C., Goto, S., Spinar, J., Nicolau, J. C., Kiss, R. G., Murphy, S. A., Wiviott, S. D., Held, P., Braunwald, E., & Sabatine, M. S.
- Affiliations
- Newark Beth Israel Medical Center (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- AstraZeneca (Sweden) (SE)
- Icahn School of Medicine at Mount Sinai (US)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Grochowski Hospital (PL)
- National Medical Research Center of Cardiology (RU)
- Justus-Liebig-Universität Gießen (DE)
- Tokai University (JP)
- Universidade de São Paulo (BR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-07
- Volume
- 372
- Issue
- 19
- Pages
- 1791-1800
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141358924
- Cited by
- 1,999
- References
- 32
- Citations by year
- 2026: 86 · 2025: 99 · 2024: 102 · 2023: 130 · 2022: 163 · 2021: 189 · 2020: 232 · 2019: 205 · 2018: 220 · 2017: 222 · 2016: 236 · 2015: 108
- FWCI
- 188.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- HAL (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (24390202)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, P2Y12 inhibitors, old myocardial infarction, dual antiplatelet therapy, long-term antiplatelet therapy, cardiovascular mortality, myocardial infarction, stroke, intracranial hemorrhage, aspirin, dose comparison, secondary prevention, bleeding risk, cardiovascular risk reduction
- MeSH terms
- Ticagrelor, Adenosine, Aged, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk, Intracranial Hemorrhages, Kaplan-Meier Estimate, Secondary Prevention, Purinergic P2Y Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
